MCID: PHR004
MIFTS: 47

Pharynx Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Pharynx Cancer

MalaCards integrated aliases for Pharynx Cancer:

Name: Pharynx Cancer 12 15
Pharyngeal Cancer 12 55
Malignant Neoplasm of Pharynx 73
Pharyngeal Neoplasms 73
Pharyngeal Carcinoma 73
Pharyngeal Neoplasm 12
Pharynx Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060119
MeSH 44 D010610
NCIt 50 C3325
SNOMED-CT 68 126685009 95001001

Summaries for Pharynx Cancer

Disease Ontology : 12 A gastrointestinal system cancer that is located in the pharynx.

MalaCards based summary : Pharynx Cancer, also known as pharyngeal cancer, is related to hypopharynx cancer and oropharynx cancer. An important gene associated with Pharynx Cancer is FAM3D-AS1 (FAM3D Antisense RNA 1
We confirmed the dysregulation of these noncoding RNAs in head and neck cancer cell linederived from different anatomic sites,and determined that ectopic expression of the two lncRNAs inhibited key EMT and stem cell genes and reduced cellular proliferation and migration.
Dysfunction Pattern: Regulation [down-regulated]), and among its related pathways/superpathways are Endometrial cancer and Glioma. The drugs Ethanol and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include the pharynx, endothelial and liver, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Related Diseases for Pharynx Cancer

Diseases in the Pharynx Cancer family:

Pharynx Carcinoma in Situ

Diseases related to Pharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
# Related Disease Score Top Affiliating Genes
1 hypopharynx cancer 32.6 CD6 MMP8 SMUG1
2 oropharynx cancer 31.4 ADH1C CD6 CDKN2A EGFR MMP8 SMUG1
3 oral cancer 29.5 CCND1 CDH1 CDKN2A EGFR GSTM1 GSTM3
4 nasopharyngeal carcinoma 28.6 AKT1 BPIFA1 BRD7 CCND1 CD79A CDH1
5 alcohol dependence 11.1
6 brain stem astrocytic neoplasm 11.0 CDKN2A TP53
7 breast papillomatosis 11.0 CCND1 CDKN2A
8 gum cancer 11.0 MMP8 SMUG1
9 gallbladder squamous cell carcinoma 11.0 SMUG1 TP53
10 bartholin's duct cyst 11.0 SMUG1 TP53
11 rare adenocarcinoma of the breast 10.9 AKT1 TP53
12 brain ependymoma 10.9 EGFR TP53
13 scrotal carcinoma 10.9 CDKN2A SMUG1 TP53
14 cerebral convexity meningioma 10.9 CDH1 TP53
15 malignant spiradenoma 10.9 SMUG1 TP53
16 anus cancer 10.9 CD6 CDKN2A SMUG1
17 anal squamous cell carcinoma 10.9 AKT1 CDKN2A TP53
18 mutagen sensitivity 10.8 CCND1 GSTM1 TP53
19 cellular ependymoma 10.8 SMUG1 TP53
20 retinal cancer 10.8 CCND1 CDKN2A TP53
21 tonsil cancer 10.8 CD6 CDKN2A
22 sensory system cancer 10.8 CCND1 CDKN2A TP53
23 cholecystitis 10.8 CDH1 CDKN2A TP53
24 basaloid squamous cell carcinoma 10.8 CDKN2A EGFR TP53
25 integumentary system cancer 10.8 AKT1 CDKN2A TP53
26 cervical squamous cell carcinoma 10.8 CDH1 CDKN2A TP53
27 vulva cancer 10.8 CDKN2A EGFR TP53
28 connective tissue cancer 10.8 AKT1 SMUG1 TP53
29 intestinal benign neoplasm 10.8 CCND1 CDH1 TP53
30 ocular cancer 10.8 CCND1 CDKN2A TP53
31 cell type benign neoplasm 10.8 CCND1 CDKN2A TP53
32 ovarian cancer 1 10.8 AKT1 CDH1 TP53
33 vulvar intraepithelial neoplasia 10.8 CDH1 TP53
34 keratinizing squamous cell carcinoma 10.8 CDKN2A TP53
35 cervical adenocarcinoma 10.7 CDKN2A EGFR TP53
36 hidradenocarcinoma 10.7 CCND1 EGFR TP53
37 malignant peritoneal mesothelioma 10.7 CDKN2A EGFR
38 oral leukoplakia 10.7 CCND1 CDKN2A GSTM1 TP53
39 breast carcinoma in situ 10.7 CDH1 EGFR TP53
40 grade iii astrocytoma 10.7 CDKN2A EGFR TP53
41 acute lymphocytic leukemia 10.7 CDKN2A GSTM1 TP53
42 thymus cancer 10.7 EGFR SMUG1 TP53
43 differentiated thyroid carcinoma 10.7 CDKN2A EGFR TP53
44 gastrointestinal system benign neoplasm 10.7 CCND1 CDH1 CDKN2A TP53
45 lynch syndrome 10.7 CCND1 CDKN2A GSTM1 TP53
46 colorectal adenocarcinoma 10.6 CDH1 EGFR TP53
47 malignant peripheral nerve sheath tumor 10.6 CDKN2A EGFR TP53
48 bowenoid papulosis 10.6 CCND1 CDKN2A
49 anaplastic oligodendroglioma 10.6 CDKN2A EGFR
50 nervous system cancer 10.6 AKT1 CCND1 CDKN2A TP53

Comorbidity relations with Pharynx Cancer via Phenotypic Disease Network (PDN):


Deficiency Anemia Larynx Cancer
Protein-Energy Malnutrition Swallowing Disorders

Graphical network of the top 20 diseases related to Pharynx Cancer:



Diseases related to Pharynx Cancer

Symptoms & Phenotypes for Pharynx Cancer

GenomeRNAi Phenotypes related to Pharynx Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CCND1 CD6 CD79A CDH1 EGFR GSTM1

MGI Mouse Phenotypes related to Pharynx Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.73 ADH1C AKT1 B4GALT5 CCND1 CD6 CD79A
2 neoplasm MP:0002006 9.28 AKT1 CCND1 CD79A CDH1 CDKN2A EGFR

Drugs & Therapeutics for Pharynx Cancer

Drugs for Pharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 48)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 3 64-17-5 702
2
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
3
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
4
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
5
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
6 Anesthetics Phase 3
7 Anesthetics, Local Phase 3
8 Antimetabolites Phase 3,Phase 2
9 Antimetabolites, Antineoplastic Phase 3,Phase 2
10 Antimitotic Agents Phase 3
11 Immunosuppressive Agents Phase 3,Phase 2
12 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
13
Cetuximab Approved Phase 2,Phase 1 205923-56-4 56842117 2333
14
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
15
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
16
Ifosfamide Approved Phase 2 3778-73-2 3690
17
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
18
Doxil Approved June 1999 Phase 2 31703
19 Analgesics Phase 1, Phase 2
20 Analgesics, Non-Narcotic Phase 1, Phase 2
21 Anti-Inflammatory Agents Phase 1, Phase 2
22 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
23 Antirheumatic Agents Phase 1, Phase 2
24 Cyclooxygenase 2 Inhibitors Phase 1, Phase 2
25 Cyclooxygenase Inhibitors Phase 1, Phase 2
26
Erlotinib Hydrochloride Phase 1, Phase 2,Early Phase 1 183319-69-9 176871
27 Mitogens Phase 1, Phase 2,Early Phase 1
28 Peripheral Nervous System Agents Phase 1, Phase 2,Not Applicable
29 Protein Kinase Inhibitors Phase 1, Phase 2,Early Phase 1
30 Alkylating Agents Phase 2
31 Anti-Bacterial Agents Phase 2
32 Antibiotics, Antitubercular Phase 2
33 Antineoplastic Agents, Alkylating Phase 2
34
Isophosphamide mustard Phase 2 0
35 Topoisomerase Inhibitors Phase 2
36
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
37
Bevacizumab Approved, Investigational Early Phase 1 216974-75-3
38
Nicotine Approved 54-11-5 942 89594
39 Lobeline Investigational Not Applicable 90-69-7
40 Angiogenesis Inhibitors Early Phase 1
41 Angiogenesis Modulating Agents Early Phase 1
42 Endothelial Growth Factors Early Phase 1
43 Autonomic Agents Not Applicable
44 Central Nervous System Stimulants Not Applicable
45 Cholinergic Agents Not Applicable
46 Neurotransmitter Agents Not Applicable
47 Nicotinic Agonists Not Applicable
48 Respiratory System Agents Not Applicable

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery Unknown status NCT00181038 Phase 3
2 Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Completed NCT00117572 Phase 3 docetaxel;cisplatin;hydroxyurea;fluorouracil
3 Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population Completed NCT00359645 Phase 3
4 Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial Recruiting NCT02765503 Phase 3
5 Concurrent Chemoradiation Versus Surgery With Adjuvant Therapy in Advanced Laryngopharyngeal Cancers Terminated NCT00128817 Phase 3
6 Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation Completed NCT00169247 Phase 2 cetuximab;Cisplatin
7 Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer Completed NCT00827164 Phase 2
8 Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer Completed NCT00970502 Phase 1, Phase 2 erlotinib + celecoxib
9 Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer Completed NCT00462735 Phase 2 Cetuximab;Hydroxyurea;Fluorouracil
10 Combination of Cryosurgey and NK Immunotherapy for Recurrent Pharyngeal Cancer Recruiting NCT02849327 Phase 1, Phase 2
11 Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma Terminated NCT00484601 Phase 2 Ifosfamide; Doxorubicin
12 Resistance Training and Physical Functioning in Head and Neck Cancer Patients Completed NCT01332682 Phase 1
13 Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer Completed NCT01445405 Phase 1 Bortezomib (Velcade, PS-341);Cetuximab;Cisplatin
14 Study of Blood and Tissue Samples From Patients With Larynx Cancer, Pharynx Cancer, or Oral Cavity Cancer Unknown status NCT00963326
15 Natural History of Oro-pharyngeal Cancer Precursors Completed NCT00179361
16 Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer Completed NCT00140556 Early Phase 1 Cisplatin;Bevacizumab;Erlotinib
17 Improvement in Knowledge and Perception About Hazards of Smokeless Tobacco Completed NCT03418506 Not Applicable
18 Pilot Study to Improve Therapeutic Outcomes for Dysphagia After Radiation Therapy Recruiting NCT02564887 Not Applicable
19 Screening for Cancers in the Oral CAvity Recruiting NCT01958762 Not Applicable
20 The Clinical Relevance of P16 Expressing CTCs Detection Comparing With HPV Infection in Cancer Tissue in HNSCC Patients. Recruiting NCT02791607
21 Patient Evaluation for Head and Neck Surgery Branch Studies Recruiting NCT00011492
22 Nicotine Levels With Response Rates to Radiation Alone or With Chemo In Head & Neck Cancer Active, not recruiting NCT01084733
23 Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/Pharyngectomy Enrolling by invitation NCT03479463
24 Carcinologic Speech Severity Index Not yet recruiting NCT02875795 Not Applicable
25 Oropharyngeal Function After Radiotherapy With IMRT Terminated NCT00506324

Search NIH Clinical Center for Pharynx Cancer

Genetic Tests for Pharynx Cancer

Anatomical Context for Pharynx Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Pharynx Cancer:

19
The Pharynx

MalaCards organs/tissues related to Pharynx Cancer:

41
Endothelial, Liver, Whole Blood

Publications for Pharynx Cancer

Articles related to Pharynx Cancer:

(show all 34)
# Title Authors Year
1
Toll-like receptor 3 stimulation triggers metabolic reprogramming in pharyngeal cancer cell line through Myc, MAPK, and HIF. ( 27805282 )
2017
2
Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer. ( 27749845 )
2016
3
Lip, oral cavity and pharyngeal cancers in the population of the city of Belgrade in the period 1999-2010. ( 26964385 )
2016
4
Immunohistochemical overexpression of hypoxia-induced factor 1I+ associated with slow reduction in (18)fluoro-2-deoxy-D-glucose uptake for chemoradiotherapy in patients with pharyngeal cancer. ( 27311919 )
2016
5
Genetic variants in microRNA-146a (C>G) and microRNA-1269b (G>C) are associated with the decreased risk of oral premalignant lesions, oral cancer, and pharyngeal cancer. ( 27525378 )
2016
6
Inaccuracies in oral cavity-pharynx cancer coded as the underlying cause of death on U.S. death certificates, and trends in mortality rates (1999-2010). ( 24862544 )
2014
7
The influence of monoamine oxidase variants on the risk of betel quid-associated oral and pharyngeal cancer. ( 25389533 )
2014
8
Oral cavity and pharynx cancer incidence trends by subsite in the United States: changing gender patterns. ( 22577381 )
2012
9
Folate, alcohol, and aldehyde dehydrogenase 2 polymorphism and the risk of oral and pharyngeal cancer in Japanese. ( 21946912 )
2012
10
Incidence of oral cavity and pharynx cancer in New Hampshire, 1990-2007. ( 23493023 )
2012
11
Role of DNA methyltransferase 1 in pharyngeal cancer related to treatment resistance. ( 21284050 )
2011
12
Lower ataxia telangiectasia mutated (ATM) mRNA expression is correlated with poor outcome of laryngeal and pharyngeal cancer patients. ( 21127011 )
2011
13
Comparison of time trends in lip, oral cavity and pharynx cancer mortality (1990-2006) between countries based on the WHO mortality database. ( 20978186 )
2010
14
The association between RCAS1 expression in laryngeal and pharyngeal cancer and its healthy stroma with cancer relapse. ( 19175908 )
2009
15
Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation. ( 19807915 )
2009
16
Incidence of oral cavity and pharynx cancer in Kentucky. ( 18783038 )
2008
17
Meta-analysis and pooled analysis of GSTM1 and CYP1A1 polymorphisms and oral and pharyngeal cancers: a HuGE-GSEC review. ( 18496222 )
2008
18
Family history and the risk of oral and pharyngeal cancer. ( 18076043 )
2008
19
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer. ( 17990317 )
2008
20
Late swallowing dysfunction and dysphagia after radiotherapy for pharynx cancer: frequency, intensity and correlation with dose and volume parameters. ( 17673322 )
2007
21
Measuring side effects after radiotherapy for pharynx cancer. ( 17882557 )
2007
22
Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer. ( 17975136 )
2007
23
Recovery issues for African Americans following treatment of oral cavity/pharynx cancer. ( 16841807 )
2006
24
Stat bite: Incidence of and mortality from oral cavity and pharynx cancer, 1975-2002. ( 16418507 )
2006
25
Oral cavity and pharynx cancer incidence rates in the United States, 1975-1998. ( 12167440 )
2002
26
The epidemiology of oral and pharynx cancer in Brazil. ( 12570051 )
2002
27
Gastroesophageal reflux disease is a risk factor for laryngeal and pharyngeal cancer. ( 11467626 )
2001
28
Glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes and the risk of smoking-related oral and pharyngeal cancers. ( 10077151 )
1999
29
Re: Alcohol dehydrogenase 3 genotype and risk of oral cavity and pharyngeal cancers. ( 9637146 )
1998
30
Alcohol dehydrogenase 3 genotype and risk of oral cavity and pharyngeal cancers. ( 9390539 )
1997
31
Pattern recognition analysis to the variation of nasal-pharynx cancer patients' trace element levels in samples of hair, whole blood, and tissue. ( 7986657 )
1994
32
Dosimetric intercomparison in the British Institute of Radiology fractionation study of 3F/week versus 5F/week in radiotherapy of laryngo-pharynx cancer. ( 2178720 )
1990
33
Indirect videolaryngoscopy versus direct endoscopy for larynx and pharynx cancer staging. Toward elimination of preliminary direct laryngoscopy. ( 2782803 )
1989
34
Survivorship with mouth and pharynx cancer and their association with cirrhosis of the liver, marital status, and residence. ( 5815753 )
1969

Variations for Pharynx Cancer

Expression for Pharynx Cancer

Search GEO for disease gene expression data for Pharynx Cancer.

Pathways for Pharynx Cancer

Pathways related to Pharynx Cancer according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.76 AKT1 CCND1 CDH1 CDKN2A EGFR TP53
2
Show member pathways
12.62 AKT1 CCND1 CDH1 CDKN2A EGFR TP53
3 12.58 AKT1 CCND1 CDH1 CDKN2A EGFR GSTM1
4
Show member pathways
12.44 AKT1 CCND1 CDH1 EGFR TP53
5
Show member pathways
12.4 AKT1 CCND1 EGFR TP53
6 12.35 AKT1 CCND1 CDKN2A TP53
7 12.29 CCND1 CDH1 CDKN2A TP53
8 12.21 AKT1 CCND1 EGFR TP53
9 12.08 AKT1 CCND1 EGFR TP53
10 12.08 AKT1 CCND1 CDKN2A TP53
11 12.05 AKT1 CCND1 CDH1 EGFR TP53
12 11.99 AKT1 GSTM1 GSTM3 TP53
13 11.99 AKT1 CCND1 CDH1 EGFR TP53
14
Show member pathways
11.94 AKT1 BRD7 CCND1 CDH1 CDKN2A EGFR
15
Show member pathways
11.86 AKT1 EGFR TP53
16 11.86 AKT1 CCND1 CDKN2A TP53
17 11.79 AKT1 CCND1 TP53
18 11.78 AKT1 CCND1 EGFR
19 11.76 AKT1 CCND1 CDKN2A EGFR TP53
20
Show member pathways
11.67 AKT1 CDKN2A TP53
21 11.61 AKT1 CCND1 EGFR
22 11.6 AKT1 EGFR TP53
23 11.51 AKT1 CCND1 TP53
24 11.47 AKT1 CCND1 TP53
25 11.42 CCND1 CDH1 CDKN2A EGFR TP53
26
Show member pathways
11.4 AKT1 BRD7 TP53
27 11.38 CCND1 CDKN2A EGFR TP53
28 11.22 AKT1 CCND1 CDH1
29 11.22 AKT1 CDKN2A GSTM1 GSTM3 TP53
30 11.18 AKT1 CDH1 EGFR
31 10.91 AKT1 CDH1 EGFR

GO Terms for Pharynx Cancer

Biological processes related to Pharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.73 AKT1 BRD7 CDH1 CDKN2A EGFR TP53
2 response to organic substance GO:0010033 9.63 AKT1 CCND1 CDH1
3 replicative senescence GO:0090399 9.43 CDKN2A TP53
4 mitotic G1 DNA damage checkpoint GO:0031571 9.4 CCND1 TP53
5 xenobiotic catabolic process GO:0042178 9.37 GSTM1 GSTM3
6 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.32 AKT1 EGFR
7 nitrobenzene metabolic process GO:0018916 9.16 GSTM1 GSTM3
8 cellular detoxification of nitrogen compound GO:0070458 8.96 GSTM1 GSTM3
9 response to UV-A GO:0070141 8.8 AKT1 CCND1 EGFR

Molecular functions related to Pharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.55 AKT1 CCND1 CDKN2A EGFR TP53
2 GTPase activating protein binding GO:0032794 9.32 AKT1 CDH1
3 glutathione binding GO:0043295 9.26 GSTM1 GSTM3
4 enzyme binding GO:0019899 9.1 AKT1 CCND1 EGFR GSTM1 GSTM3 TP53
5 nitric-oxide synthase regulator activity GO:0030235 8.96 AKT1 EGFR

Sources for Pharynx Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....